BiotechTube

E2027

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lewy Body Disease

Conditions

Lewy Body Disease, Parkinson Disease

Trial Timeline

Feb 25, 2021 → Jan 27, 2022

NCT ID
NCT04764669

About E2027

E2027 is a phase 2 stage product being developed by Eisai for Lewy Body Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04764669. Target conditions include Lewy Body Disease, Parkinson Disease.

What happened to similar drugs?

1 of 3 similar drugs in Lewy Body Disease were approved

Approved (1) Terminated (0) Active (2)
✅E2020 + PlaceboEisaiApproved
🔄Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
🔄ACP-204Acadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04764669Phase 2Completed
NCT04023877Phase 1Completed

Competing Products

13 competing products in Lewy Body Disease

See all competitors
ProductCompanyStageHype Score
E2020 + PlaceboEisaiApproved
43
Donepezil HydrochlorideEisaiPre-clinical
26
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
40
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + PlaceboEisaiPhase 2
35
Irsenontrine + PlaceboEisaiPhase 2
35
E2020EisaiPhase 2
35
E2027EisaiPhase 1
29
LY3154207 + PlaceboEli LillyPhase 2
35
HTL0018318 + PlaceboNxera PharmaPhase 2
27
ACP-204Acadia PharmaceuticalsPhase 3
44
ACP-204 + PlaceboAcadia PharmaceuticalsPhase 2
39
Neflamapimod + PlaceboCervoMedPhase 2
25
neflamapimodCervoMedPhase 2
29